Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.60 USD
-0.08 (-4.76%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $1.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Lexicon Pharmaceuticals, Inc. [LXRX]
Reports for Purchase
Showing records 301 - 320 ( 396 total )
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
January and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
January and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&D Day Highlighted Pipeline Progress; Next: In Q1 Additional Phase 2 Results for LX4211 in T1D; Reiterate OUTPERFORM And $4 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
December 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
December 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 25
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials Were in Line; Next: Phase 2 LX1033 Results for IBS-d in November
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mechanistic Data Suggests SGLT1 Co-Inhibition with SGLT2 Significantly Increases Reduction of Blood Glucose; ReiterateOUTPERFORM and $4 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mechanistic Data Suggests SGLT1 Co-Inhibition with SGLT2 Significantly Increases Reduction of Blood Glucose; Reiterate OUTPERFORM and $4 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
November and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
November and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L